Literature DB >> 18206693

Risk factors in preventable adverse drug events in pediatric outpatients.

Stephanie O Zandieh1, Donald A Goldmann, Carol A Keohane, Catherine Yoon, David W Bates, Rainu Kaushal.   

Abstract

OBJECTIVE: To determine whether there are racial/ethnic, socioeconomic, parental linguistic, or parental educational disparities in children who experienced an adverse drug event (ADE) in the ambulatory setting. STUDY
DESIGN: We conducted a prospective cohort study of pediatric patients <21 years seen during 2-month study periods from July 2002 to April 2003 at 6 office practices in Boston. The primary outcome measure was ADEs. Descriptive analysis of patient characteristics and types of ADEs experienced was followed by multivariate analysis to determine risk factors associated with presence of a preventable ADE.
RESULTS: A total of 1689 patients receiving 2155 prescriptions were analyzed via a survey and chart review. Overall, 242 children (14%) experienced an ADE, of which 55 (23%) had a preventable ADE and 186 (77%) had a non-preventable ADE. In multivariate analysis, children with multiple prescriptions (odds ratio, 1.46; 95% CI, 1.01-2.11) were at increased risk of having a preventable ADE, controlling for parental education, racial/ethnic, English proficiency, practice type, and duration of care.
CONCLUSIONS: Children with multiple prescriptions are at increased risk of having a preventable ADE. Further attention should be directed toward improved communication among healthcare providers and patients.

Entities:  

Mesh:

Year:  2007        PMID: 18206693     DOI: 10.1016/j.jpeds.2007.09.054

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  23 in total

1.  Evaluating the accuracy of electronic pediatric drug dosing rules.

Authors:  Eric S Kirkendall; S Andrew Spooner; Judith R Logan
Journal:  J Am Med Inform Assoc       Date:  2013-06-28       Impact factor: 4.497

2.  Adverse drug events in the outpatient setting: an 11-year national analysis.

Authors:  Florence T Bourgeois; Michael W Shannon; Clarissa Valim; Kenneth D Mandl
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-09       Impact factor: 2.890

Review 3.  Electronic prescribing in pediatrics: toward safer and more effective medication management.

Authors:  Kevin B Johnson; Christoph U Lehmann
Journal:  Pediatrics       Date:  2013-03-25       Impact factor: 7.124

Review 4.  Methods for assessing the preventability of adverse drug events: a systematic review.

Authors:  Katja Marja Hakkarainen; Karolina Andersson Sundell; Max Petzold; Staffan Hägg
Journal:  Drug Saf       Date:  2012-02-01       Impact factor: 5.606

Review 5.  Categorization and association analysis of risk factors for adverse drug events.

Authors:  Lina Zhou; Anamika Paul Rupa
Journal:  Eur J Clin Pharmacol       Date:  2017-12-08       Impact factor: 2.953

Review 6.  Considerations for Providing Ambulatory Pharmacy Services for Pediatric Patients.

Authors:  Stacie J Lampkin; Brooke Gildon; Sandra Benavides; Kelly Walls; Leslie Briars
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jan-Feb

7.  Patient perceptions of mistakes in ambulatory care.

Authors:  Christine E Kistler; Louise C Walter; C Madeline Mitchell; Philip D Sloane
Journal:  Arch Intern Med       Date:  2010-09-13

Review 8.  Racial and Ethnic Disparities in Adverse Drug Events: A Systematic Review of the Literature.

Authors:  Avi Baehr; Juliet C Peña; Dale J Hu
Journal:  J Racial Ethn Health Disparities       Date:  2015-03-24

9.  Health literacy predicts pediatric dosing accuracy for liquid zidovudine.

Authors:  Leigh M Howard; José A Tique; Sandra Gaveta; Mohsin Sidat; Russell L Rothman; Sten H Vermund; Philip J Ciampa
Journal:  AIDS       Date:  2014-04-24       Impact factor: 4.177

10.  Health IT Usability Focus Section: Adapting EHR-Based Medication Instructions to Comply with Plain Language Guidance-A Randomized Experiment.

Authors:  Jessica S Ancker; Alexander Send; Baria Hafeez; Snezana N Osorio; Erika Abramson
Journal:  Appl Clin Inform       Date:  2017-12-14       Impact factor: 2.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.